Ionis Pharmaceuticals (IONS) PT Lifted to $46 at Piper Jaffray
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Piper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $46.00 (from $36.00) following Q2 earnings and an update on its antisense pipeline.
Schimmer commented, "The company provided some color on nusinersen for the treatment of infants with Type I spinal muscular atrophy (SMA) as it transitions the program to Biogen, ahead of regulatory applications in the U.S. and E.U. in the coming months. The second half of 2016 holds multiple catalysts for IONS as it shifts its pipeline towards lica and generation 2.5 chemistry and advances its programs toward a regulatory pathway. The company affirmed its financial guidance and reported cash and cash equivalents totaling $664M. We reiterate our OW rating and increase our PT from $35 to $46 as we increase the nusinersen royalty to reflect increases we made to sales in our BIIB model (our terminal growth assumption was lowered from 7% to 6.5% and the discount rate of 11.5% is unchanged)."
Shares of Ionis Pharmaceuticals closed at $36.33 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Cowen Downgrades Under Armour, Inc. (UA) to Market Perform
- FBR Capital Remains Bullish Following Select Income REIT's (SIR) 3Q Miss
- Wedbush Cuts Price Target on Polaris Industries (PII) Following 3Q Report
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesPiper Jaffray, Earnings, Joshua Schimmer
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!